<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002066</url>
  </required_header>
  <id_info>
    <org_study_id>015A</org_study_id>
    <secondary_id>07 32 005</secondary_id>
    <nct_id>NCT00002066</nct_id>
  </id_info>
  <brief_title>Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection</brief_title>
  <official_title>Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunobiology Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      Examine the ability of thymopentin (Timunox) to:

      Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter
      the clinical findings in patients infected with HIV who do not yet have AIDS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymopentin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine.

        Prior Medication:

        Allowed:

          -  Aerosolized pentamidine.

        Exclusion Criteria

        Co-existing Condition:

        Patients with an abnormal chest x-ray indicative of active disease (opportunistic
        infection) within 30 days prior to entry are excluded.

        Concurrent Medication:

        Excluded within 90 days of study entry:

          -  Zidovudine (AZT).

        Prior Medication:

        Excluded within 30 days of study entry:

          -  Immunomodulatory or experimental therapy.

          -  Excluded within 90 days of study entry:

          -  Zidovudine (AZT).

        Patients must not have:

          -  Hemophilia A or B or other hematologic disorders requiring current or previous
             administration of blood products.

          -  AIDS as defined by the CDC (except for those with HIV &quot;wasting syndrome&quot;).

          -  Significant hepatic disease.

          -  Thrombocytopenia (&lt; 75000 platelets/mm3).

        Patient must voluntarily sign consent and be seropositive for HIV-1 (ELISA assay) confirmed
        by Western blot.

          -  HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's
             peripheral blood monocytes (PBMC) on two separate occasions.

          -  Patients with HIV &quot;wasting syndrome&quot; are included.

        Intravenous drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Immunobiology Research Institute</name>
      <address>
        <city>Annandale</city>
        <state>New Jersey</state>
        <zip>088010999</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1989</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Thymopentin</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymopentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

